Australian Biotechnology Company, Spinifex Pharmaceuticals has announced it has received an R&D Tax Incentive of approximately AUS$1.5 million. The Melbourne company established in June 2005 develops new medicinal drugs for the treatment and management of pain. The funds will be reinvested in further clinical development. Spinifex Pharmaceuticals CEO Tom McCarthy said: “This payment under the R&D tax incentive program is a good example of how Government initiatives can support innovative companies in the biotechnology industry and other sectors”. Click here […]
As the R&D Incentive deadline looms, companies are reminded that they need to register before 30 April to be eligible to claim for R&D activities for the 2012 financial year. This is the first year the benefits of the new R&D Tax Incentive will be seen. The R&D Tax Incentive (which replaced the R&D Tax Concession), provides generous support for companies who spent over $20,000 on experimental activities in FY2012. Companies with an aggregated turnover of less $20 million could […]
With the government’s recent R&D cuts from groups with revenue over $20 billion, there is some uncertainty surrounding the Australia’s commitment to research and development. A recent article in the Australian Financial Review explores the possibility that Australian businesses might look to invest elsewhere where R&D tax credits are more stable.
Click here for the Swanson Reed R&D Tax Incentive Quarterly Credits Submission.